Sultan Qaboos University Hospital

Running trials

• Not yet recruiting

  Nortriptyline Compared With Amitriptyline for Migraine Prevention at SQUH

  NCT07856056· Phase 4· Sultan Qaboos University· Source

• Not yet recruiting

  Nebulized Ketamine for Severe Asthma Attacks in Children

  NCT07728851· Phase 2· Sultan Qaboos University· Source

• Not yet recruiting

  Telehealth Educational Intervention for Adults With Type 2 Diabetes in Oman

  NCT07793292· Sultan Qaboos University· Source

• Not yet recruiting

  Feasibility and Effectiveness of an AI-Powered Carbohydrate Counting Educational Platform to Support Parents of Children With Type 1 Diabetes

  NCT07671053· Sultan Qaboos University· Source

• Recruiting

  A Real-World Study to Evaluate Luspatercept in Adults With Transfusion-Dependent Beta-Thalassemia in the Middle East

  NCT07215975· Bristol-Myers Squibb· Source

• Recruiting

  Nebulized Ketamine Plus Standard Care vs. Standard Care Alone in Moderate to Severe Asthma Exacerbations

  NCT07112456· Phase 2· Oman Medical Speciality Board· Source

• Not yet recruiting

  Oral Bisoprolol Vs IV Diltiazem in Atrial Fibrillation or Flutter With Rapid Ventricular Rate.

  NCT06276127· Phase 3· Oman Medical Speciality Board· Source

• Recruiting

  A Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease

  NCT06612268· Phase 3· Novo Nordisk A/S· Source

• Recruiting

  A Research Study Looking at Long-term Treatment With Etavopivat in People With Sickle Cell Disease or Thalassaemia

  NCT06609226· Phase 3· Novo Nordisk A/S· Source

• Recruiting

  A Phase 2 Open-label Study to Evaluate the Activity of Etavopivat on Transcranial Doppler Velocities in Pediatric Patients With Sickle Cell Disease Who Are at Increased Risk for Primary Stroke

  NCT05953584· Phase 2· Forma Therapeutics, Inc.· Source

• Active, not recruiting

  A Study Evaluating the Efficacy and Safety of Mitapivat (AG-348) in Participants With Sickle Cell Disease (RISE UP)

  NCT05031780· Phase 2/3· Agios Pharmaceuticals, Inc.· Source

• Recruiting

  Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without Inhibitors

  NCT05145127· Phase 3· Pfizer· Source

• Active, not recruiting

  A Study of Etavopivat in Adults and Adolescents With Sickle Cell Disease (HIBISCUS)

  NCT04624659· Phase 3· Forma Therapeutics, Inc.· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Sickle cell disease3 recruiting
• Asthma2 recruiting
• Thalassaemia2 recruiting
• Atrial fibrillation1 recruiting
• Haemophilia1 recruiting
• Migraine1 recruiting
• Stroke1 recruiting
• Type 1 diabetes1 recruiting
• Type 2 diabetes1 recruiting

Closed trials

• Completed

  Research Study Investigating How Well NDec Works in People With Sickle Cell Disease

  NCT05405114· Phase 2· Novo Nordisk A/S· Source

• Terminated

  A Study to Evaluate the Long-term Safety of Inclacumab Administered to Participants With Sickle Cell Disease

  NCT05348915· Phase 3· Pfizer· Source

• Terminated

  A Study of a Single Dose of Inclacumab to Reduce Re-admission in Participants With Sickle Cell Disease and Recurrent Vaso-occlusive Crises

  NCT04927247· Phase 3· Pfizer· Source

• Completed

  A Study to Assess the Safety and Efficacy of Inclacumab in Participants With Sickle Cell Disease Experiencing Vaso-occlusive Crises

  NCT04935879· Phase 3· Pfizer· Source

• Terminated

  Study to Evaluate the Effect of GBT440 on TCD in Pediatrics With Sickle Cell Disease

  NCT04218084· Phase 3· Pfizer· Source

• Completed

  Study of the Efficacy and Safety PF-06741086 in Adult and Teenage Participants With Severe Hemophilia A or Moderately Severe to Severe Hemophilia B

  NCT03938792· Phase 3· Pfizer· Source

• Terminated

  Study to Assess the Effect of Long-term Treatment With Voxelotor in Participants Who Have Completed Treatment in Study GBT440-031

  NCT03573882· Phase 3· Pfizer· Source

Conditions

Diseases this institution publishes on or runs trials for.

• Sickle cell disease9 works · 11 trials